AI Article Synopsis
- The study investigates the outcomes of neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) in patients with locally advanced rectal cancer (LARC) after undergoing curative surgery.
- A total of 252 patients were reviewed, with 51 patients matched for comparison, revealing that those who received NAC had longer surgery times, more blood loss, and a higher percentage receiving AC.
- The results indicated that patients who received both NAC and AC had significantly better three-year recurrence-free survival rates (90.2%) compared to those who only received AC or none at all, suggesting that NAC and AC can enhance treatment outcomes for LARC.
Article Abstract
Background/aim: The effect of neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) for locally advanced rectal cancer (LARC) is not fully understood. This study aimed to identify outcomes following NAC plus AC for LARC.
Patients And Methods: We reviewed 252 patients who underwent curative resection for LARC. Propensity score matching matched 51 patients in NAC and non-NAC groups.
Results: Operative time (443 min vs. 286 min, p<0.001), blood loss (279 ml vs. 124 ml p<0.001), and number of patients who received AC were higher in the NAC group (74.5% vs. 33.3%, p<0.001). The Disease control rate of NAC group was 98.1%. The NAC group showed better 3-year RFS (86.5% vs. 62.1%, p=0.021). Patients who received both NAC and AC displayed better 3-year RFS (90.2%) compared to the non-NAC group both with (63.8%) and without (60.4%) AC (p<0.05).
Conclusion: NAC and AC for LARC have the potential to improve oncological outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.15625 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!